ONCOLYTICS COMPLETES ENROLMENT IN CANCER DRUG PHASE I TRIAL

Oncolytics Biotech Inc. has completed patient enrolment in its Phase I U.S. clinical trial investigating the systemic delivery of Reolysin to treat patients with advanced cancers. A total of 18 patients were treated at escalating dosages. A maximum tolerated dose (MTD) was not reached, and the treatment appears to have been well-tolerated by the patients.

The trial is an open-label study in which a single dose of the drug was administered intravenously to patients diagnosed with selected advanced or metastatic solid tumours that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists. The primary objective of the study is to determine the MTD, dose-limiting toxicity and safety profile of Reolysin. Secondary objectives include the evaluation of viral replication, immune response to the virus and any evidence of anti-tumor activity.